Business Context and Reporting Period
This Form 8-K is a current report filed by Aikido Pharma, Inc. (not Dominari Holdings Inc.) on July 2, 2021. The filing reports on an event occurring on June 28, 2021, regarding an amendment to the employment agreement of the Company's Chief Executive Officer, Anthony Hayes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
- Executive Compensation Increase: The annual base salary for CEO Anthony Hayes was increased to $500,000.
- Contract Extension: The term of the CEO's employment agreement was extended to June 28, 2024.
- Additional Incentives: The CEO is now entitled to certain additional milestone and performance-based fees as detailed in the amendment.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is the execution of the amended employment agreement, which is filed as Exhibit 10.1. The Company is not an emerging growth company.
Investor Verification Checklist
- Verify the specific terms of the milestone and performance-based fees in Exhibit 10.1 (Amendment No. 3 to the Employment Agreement).
- Confirm the total potential payout implications of the new compensation structure against the Company's current cash position.
- Review the original employment agreement history (dated 2013, amended 2016 and 2017) to understand the trajectory of compensation changes.